Abstract

The aim of this study was to compare more conclusively the efficacy and safety of moxifloxacin, a new respiratory fluoroquinolone antibiotic with levofloxacin therapy which has been reported to possess good efficacy for community acquired pneumonia (CAP) in hospitalized elderly patient. The entire patients were mild to moderate by CAP. All the trials administered intravenously moxifloxacin (400 mg daily) and intravenously levofloxacin (200- 500 mg daily) for 7-14 days. Clinical response during therapy was between days 3 and 5 after the start of therapy. A meta-analysis of randomized controlled trials (RCTs, identified in CNKI, PubMeD, Embase, Google) were performed. Eight RCTs involving 1310 patients were included in meta- analysis. Two reviewers independently extracted data from published trials that compared fluoroquinolones. A meta-analysis was performed with the clinical outcomes of moxifloxacin and levofloxacin. Moxifloxacin monotherapy was associated with better therapeutic effect [(OR=1.63, 95%CI 1.01-2.63) and similar adverse effect (OR=1.12, 95%CI 0.81-1.55)] compared with levofloxacin therapy for CAP. Moxifloxacin has better therapeutic effects with comparable adverse events compared tolevofloxacin.

Key words: Moxifloxacin, levofloxacin, randomized control trial, community acquired pneumonia.